Osteoporosis

What is Osteoporosis?

Osteoporosis is a progressive bone disease characterized by decreased bone density and deterioration of bone tissue, leading to increased fracture risk. Often called a “silent disease,” osteoporosis typically develops without symptoms until a fracture occurs. The condition primarily affects older adults, particularly postmenopausal women, though it can occur in men and younger individuals. Osteoporosis affects over 200 million people worldwide, making it one of the most common bone diseases globally.

Key statistics

Symptoms

Common presentation: Back pain, loss of height, stooped posture, bone fractures from minor trauma, kyphosis (hunched back).

Osteoporosis is often asymptomatic in its early stages, earning its reputation as a silent disease. The first sign is frequently a fracture that occurs with minimal trauma, such as a fall from standing height or even coughing or sneezing. Chronic back pain may develop due to vertebral compression fractures, which can occur spontaneously or with minor stress. Patients often notice gradual height loss, sometimes up to several inches, as vertebrae compress. A stooped or hunched posture (kyphosis) may develop as multiple vertebral fractures accumulate. Some individuals experience acute, severe back pain when vertebral fractures occur suddenly. Advanced osteoporosis can lead to difficulty performing daily activities and increased fear of falling.

Causes and risk factors

Osteoporosis results from an imbalance between bone formation and bone resorption, where bone breakdown exceeds bone building. Primary osteoporosis occurs naturally with aging and hormonal changes, particularly the decline in estrogen during menopause. Secondary osteoporosis results from underlying medical conditions or medications.

Submit Your Paper

Major risk factors include: Advanced age, female gender, postmenopausal status, family history of osteoporosis, small body frame, Caucasian or Asian ethnicity, smoking, excessive alcohol consumption, sedentary lifestyle, and low calcium or vitamin D intake. Medical conditions that increase risk include rheumatoid arthritis, celiac disease, inflammatory bowel disease, chronic kidney disease, hyperthyroidism, and hyperparathyroidism. Medications associated with bone loss include long-term corticosteroids, anticonvulsants, proton pump inhibitors, and certain cancer treatments. Genetic factors play a significant role, with peak bone mass largely determined by heredity.

Prevention

Evidence-based prevention strategies focus on maximizing peak bone mass in youth and minimizing bone loss in adulthood. Adequate calcium intake (1,000-1,200 mg daily for adults) and vitamin D supplementation (800-1,000 IU daily) are fundamental. Weight-bearing and resistance exercises help build and maintain bone density throughout life. Lifestyle modifications include smoking cessation, limiting alcohol consumption, maintaining healthy body weight, and preventing falls through home safety measures and balance training.

Bone density screening with DEXA scans is recommended for all women aged 65 and older, men aged 70 and older, and younger individuals with risk factors. The U.S. Preventive Services Task Force recommends screening for postmenopausal women under 65 using fracture risk assessment tools. Early identification allows for preventive interventions before fractures occur.

Complications

Without treatment, osteoporosis leads to increasingly frequent and severe fractures with progressively less trauma required to cause breaks. Hip fractures are among the most serious complications, with 20% mortality within one year and significant disability among survivors. Vertebral compression fractures can cause chronic pain, height loss, spinal deformity, and reduced quality of life. Multiple vertebral fractures may compress internal organs, affecting breathing and digestion.

Fracture-related complications include prolonged immobility, muscle weakness, blood clots, pneumonia, and depression. The fear of falling often leads to reduced physical activity, social isolation, and further bone loss, creating a dangerous cycle. Each osteoporotic fracture significantly increases the risk of subsequent fractures, with vertebral fractures increasing future vertebral fracture risk by five-fold and hip fracture risk by two-fold.

Diagnosis

Osteoporosis diagnosis relies primarily on bone mineral density (BMD) testing using dual-energy X-ray absorptiometry (DEXA) scans. The World Health Organization defines osteoporosis as a T-score of -2.5 or lower at the spine, hip, or forearm. Osteopenia (low bone mass) is defined as a T-score between -1.0 and -2.5.

Laboratory tests help identify secondary causes and include complete blood count, comprehensive metabolic panel, 25-hydroxyvitamin D, parathyroid hormone, thyroid function tests, and 24-hour urine calcium. Bone turnover markers such as C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) may be used to monitor treatment response. Vertebral fracture assessment using lateral spine imaging can detect existing vertebral fractures. Plain radiographs may reveal fractures or bone loss but are less sensitive than DEXA for early detection.

Treatment

Treatment aims to prevent fractures by increasing bone density and reducing fall risk. First-line medications include bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid. These drugs reduce bone resorption and significantly decrease fracture risk.

Alternative medications include denosumab, a RANKL inhibitor given as twice-yearly injections, and raloxifene, a selective estrogen receptor modulator primarily used in postmenopausal women. For severe osteoporosis, anabolic agents like teriparatide and abaloparatide stimulate bone formation. Romosozumab is a newer agent that both increases bone formation and decreases bone resorption.

Calcium and vitamin D supplementation support all treatments. Physical therapy focusing on balance, strength, and fall prevention is essential. Vertebroplasty or kyphoplasty may be considered for painful vertebral compression fractures.

Prognosis

With appropriate treatment, osteoporosis prognosis is generally favorable. Anti-resorptive medications can reduce vertebral fracture risk by 40-70% and hip fracture risk by 40-50%. Treatment typically increases bone density by 3-8% over 2-3 years, though fracture risk reduction often occurs before significant density changes.

Without treatment, bone loss continues at 1-3% annually, with accelerated loss in early postmenopausal years. Untreated osteoporosis leads to progressive fracture risk, with lifetime fracture probability reaching 40-50% in women and 13-22% in men over age 50. Hip fractures carry the highest morbidity and mortality, with many patients never returning to their pre-fracture functional level. However, early intervention and adherence to treatment significantly improve long-term outcomes and quality of life.

Quality of life

Living with osteoporosis requires proactive lifestyle adaptations to maintain independence and prevent fractures. Regular weight-bearing exercise such as walking, dancing, or tennis, combined with resistance training, helps maintain bone and muscle strength. Balance exercises like tai chi reduce fall risk while improving confidence and mobility.

Home modifications include removing trip hazards, installing grab bars and adequate lighting, using non-slip mats, and ensuring sturdy handrails on stairs. Proper footwear with good support and traction is essential. Dietary focus should include calcium-rich foods like dairy products, leafy greens, and fortified foods, along with adequate protein intake to support bone health.

Mental health support is crucial, as chronic pain and fracture fear can lead to depression and anxiety. Support groups, counseling, and maintaining social connections help combat isolation. Many patients benefit from pain management strategies including heat therapy, gentle stretching, and stress reduction techniques. Occupational therapy can provide adaptive equipment and techniques for daily activities.

Pregnancy and fertility

Osteoporosis typically affects older adults, but pregnancy and breastfeeding can impact bone health in younger women. During pregnancy and lactation, calcium demands increase significantly, potentially affecting maternal bone density if intake is inadequate. Most osteoporosis medications are contraindicated during pregnancy and breastfeeding.

Women with osteoporosis who become pregnant should ensure adequate calcium (1,300 mg daily) and vitamin D intake, continue weight-bearing exercise as appropriate, and work closely with their healthcare team. Pregnancy-associated osteoporosis is rare but can occur, particularly with prolonged breastfeeding. Bone density typically recovers after weaning, though monitoring may be necessary for women with additional risk factors.

Children

Childhood and adolescence are critical periods for bone accrual, with 90% of peak bone mass achieved by age 18-20. Juvenile osteoporosis is rare but can occur due to genetic disorders, chronic diseases, medications (particularly corticosteroids), or lifestyle factors.

Primary juvenile osteoporosis typically presents between ages 8-14 with bone pain, fractures, and sometimes difficulty walking. Secondary juvenile osteoporosis may result from conditions like osteogenesis imperfecta, endocrine disorders, or prolonged immobilization. Treatment focuses on addressing underlying causes, ensuring adequate nutrition, promoting physical activity, and sometimes using bisphosphonates in severe cases.

Prevention in children emphasizes adequate calcium and vitamin D intake, regular physical activity, and avoiding smoking and excessive alcohol in adolescents. School accommodations may be necessary for children with severe bone fragility to prevent injury during activities.

When to see a doctor

Seek immediate medical attention for sudden, severe back or hip pain that may indicate fracture, inability to bear weight after a fall, or significant height loss over a short period. Urgent evaluation is needed for fractures following minor trauma, as this may be the first sign of osteoporosis.

Routine medical consultation is appropriate for postmenopausal women, men over 70, or anyone with risk factors for osteoporosis. Early evaluation allows for prevention strategies and treatment before fractures occur. Regular follow-up is essential for those already diagnosed to monitor treatment effectiveness and adjust therapy as needed.

Regional context

Limited specific data exists for osteoporosis prevalence in the Caucasus region, though studies suggest rates similar to other European populations. Georgia, Armenia, and Azerbaijan face challenges with vitamin D deficiency due to limited sunlight exposure in mountainous regions and dietary factors. Traditional diets in these regions may provide variable calcium intake depending on dairy consumption patterns.

Healthcare infrastructure for bone density testing and specialized osteoporosis care may be limited in rural areas. GMJ welcomes contributions from regional researchers to build the evidence base for osteoporosis in the Caucasus.

Research and clinical trials

Current research focuses on novel therapeutic targets, personalized treatment approaches, and improved fracture prediction models. Promising areas include sclerostin inhibitors, cathepsin K inhibitors, and combination therapies. Researchers are investigating optimal treatment duration, drug holidays, and sequential therapy strategies.

Recent breakthroughs include the development of romosozumab, which both builds and preserves bone, and improved understanding of genetic factors influencing fracture risk. Artificial intelligence applications for fracture risk prediction and automated vertebral fracture detection on imaging are emerging technologies.

Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Participation in research helps advance treatment options and may provide access to promising new therapies.

Frequently asked questions

Can osteoporosis be reversed?

While osteoporosis cannot be completely “cured,” effective treatments can significantly improve bone density, reduce fracture risk, and prevent progression. Some patients may see T-scores improve enough to move from osteoporotic to osteopenic ranges.

How long should I take osteoporosis medications?

Treatment duration varies by individual risk factors and medication type. Bisphosphonates are often taken for 3-5 years initially, with drug holidays considered for some patients. Your doctor will monitor your response and adjust treatment accordingly.

Is exercise safe with osteoporosis?

Yes, appropriate exercise is essential for bone health. Weight-bearing and resistance exercises are beneficial, while high-impact activities and forward spinal flexion should be avoided. Physical therapy can help design safe exercise programs.

Do I need calcium supplements if I take osteoporosis medication?

Most patients benefit from calcium and vitamin D supplementation to support bone health, though some medications require adequate calcium for optimal effectiveness. Your doctor will recommend appropriate dosing based on dietary intake and individual needs.

Will I definitely have fractures if I have osteoporosis?

Having osteoporosis increases fracture risk but doesn’t guarantee fractures will occur. Effective treatment, fall prevention, and lifestyle modifications significantly reduce fracture probability and help many patients avoid breaks entirely.

Support and resources

International Osteoporosis Foundation: https://www.osteoporosis.foundation/
National Osteoporosis Foundation: https://www.nof.org/
Bone Health and Osteoporosis Foundation: https://www.bonehealthandosteoporosis.org/
European Society for Clinical and Economic Aspects of Osteoporosis: https://www.esceo.org/
World Health Organization: https://www.who.int/

These organizations provide patient education materials, support group information, exercise guidelines, and updates on treatment advances. Many offer resources in multiple languages and have local chapters worldwide.

Related conditions

Osteopenia – Low bone mass that precedes osteoporosis, requiring monitoring and preventive interventions.
Osteogenesis imperfecta – Genetic disorder causing brittle bones and frequent fractures from childhood.
Paget’s disease – Bone disorder causing enlarged, weakened bones due to abnormal bone remodeling.
Hyperparathyroidism – Overactive parathyroid glands leading to calcium imbalance and bone loss.
Vitamin D deficiency – Common condition that impairs calcium absorption and bone health.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.